Showing 2991-3000 of 3039 results for "".
- Alzheimer’s Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Boardhttps://modernod.com/news/alzheimers-therapeutics-research-leader-dr-roy-twyman-joins-neurovision-imaging-board/2480013/Roy Ervin Twyman, MD, PhD, an academic neurologist with nearly 20 years’ experience in neuroscience pharmaceutical drug development, will join the NeuroVision Imaging Board of Directors on July 20. NeuroVision is developing and studying an experimental, breakthrough, low-cost, noninvasive,
- BlephEx Names Fred Ellis CEOhttps://modernod.com/news/blephex-names-fred-ellis-ceo/2480014/BlephEx has announced that Fred Ellis is the company’s new CEO. Mr. Ellis comes to BlephEx with 29+ years of experience with Alcon-Novartis. While there, he held numerous positions of increased responsibility overseeing a wide range of commercial assignments. He is recognized for having exception
- American Academy of Optometry Announces 2018 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2018-award-recipients/2480026/Each year the American Academy of Optometry recognizes distinguished individuals who have made countless important contributions to advancing the profession of optometry. “Every nominee represents exactly what the American Academy
- Oyster Point Announces Positive Results from Phase 2 Clinical Trial of Investigational Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-announces-positive-results-from-phase-2-clinical-trial-of-investigational-treatment-for-dry-eye-disease/2480029/Oyster Point Pharma announced results from the PEARL study, a phase 2b clinical trial evaluating the company’s novel therapy for the treatment of dry eye disease (DED). The study met both sign and symptom primary endpoints by showing a statistically significant improvement in each compared to a v
- Some Companies Cancel, Reduce Planned Price Hikes Amid Continued Pressure Over US Drug Costs: Reporthttps://modernod.com/news/some-companies-cancel-reduce-planned-price-hikes-amid-continued-pressure-over-us-drug-costs-report/2480031/Novartis, Gilead Sciences, Roche, and Novo Nordisk have advised California health plans in recent weeks that the companies are rescinding or reducing previously announced price increases on at least 10 drugs, Bloomberg reported Tuesday. The moves come after California introduced legislation earli
- EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ for Posterior Segment Uveitis to be Presented at ASRShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-for-posterior-segment-uveitis-to-be-presented-at-asrs/2480032/EyePoint Pharmaceuticals announced that three abstracts supporting the company’s YUTIQ (fluocinolone acetonide intravitreal implant) 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the 36th Annual Scientific Meeting of the American Soci
- Former P&G And Cincinnati Children’s Executive Katherine Overbey Joins OneSight As President And Executive Directorhttps://modernod.com/news/former-pg-and-cincinnati-childrens-executive-katherine-overbey-joins-onesight-as-president-and-executive-director/2480057/Global vision care nonprofit OneSight announced that Katherine “K-T” Overbey will be joining the organization as President and Executive Director. Ms. Overbey brings a distinct blend of blue-chip corporate and nonprofit experience in both developed and emerging markets, as well as a s
- ThromboGenics Plans Name Change to “Oxurion”https://modernod.com/news/thrombogenics-plans-name-change-to-oxurion/2480064/ThromboGenics announced its intention to change its name to “Oxurion” and the company’s stock ticker symbol from ‘THR” to “OXUR.” The company issued a convening notice seeking the approval of ThromboGenics’ shareholders for the name change at an Extraordinary Genera
- Alcon to Showcase New Products, Commitment to ECP Education at 2018 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-new-products-commitment-to-ecp-education-at-2018-optometrys-meeting/2480083/Alcon will introduce new products and educational resources to eye care professional (ECP) and paraoptometric audiences at this year’s American Optometric Association (AOA) Optometry’s Meeting taking place June 20-24 in Denver. Notably, Leatrice Eiseman, executive director at the Pantone C
- Optovue Announces Expanded FDA Clearance of Epithelial Thickness Mappinghttps://modernod.com/news/optovue-announces-expanded-fda-clearance-of-epithelial-thickness-mapping/2480088/Optovue announced an expanded FDA 510(k) clearance for non-contact, quantitative measurements of the epithelial and stromal layers of the cornea, termed epithelial thickness mapping (ETM). The expanded clearance adds a 9-millimeter ETM scan to the previously available 6-millimeter map, allowing f